Publicaciones en colaboración con investigadores/as de Hospital Universitario Reina Sofia (18)

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

2023

  1. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

2022

  1. Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain

    Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 495-502

2021

  1. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications

    JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169

  2. Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain

    Revista de la Sociedad Espanola del Dolor, Vol. 28, pp. 19-26

2020

  1. Treatment patterns for metastatic colorectal cancer in Spain

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1455-1462

2019

  1. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 380-390

2018

  1. Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii611-viii612

  2. Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii612

  3. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

    British Journal of Cancer, Vol. 119, Núm. 12, pp. 1464-1470

  4. The quality oncology practice initiative program: Experience in Spain

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii570-viii571

2010

  1. Consensus document on the use of biosimilar granulocyte-colony stimulating factor for the correction of neutropenia associated in cancer patients

    Farmacia Hospitalaria, Vol. 34, Núm. SUPPL. 1, pp. 45-50

2009

  1. Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer

    Lung Cancer, Vol. 63, Núm. 1, pp. 83-87

2004

  1. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: Randomized phase II trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study

    Annals of Oncology, Vol. 15, Núm. 1, pp. 79-87

  2. Prospective randomised phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer

    Clinical Lung Cancer, Vol. 6, Núm. 3, pp. 175-183

  3. Single nucleotide polymorphisms and outcome in docetaxel - Cisplatin-treated advanced non-small-cell lung cancer

    Annals of Oncology, Vol. 15, Núm. 8, pp. 1194-1203

2003

  1. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group

    Annals of Oncology, Vol. 14, Núm. 6, pp. 833-842

1992

  1. Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: Activity in liver metastasis: Original article

    Cancer Investigation, Vol. 10, Núm. 4, pp. 259-264